Australian government signs an agreement with Merck Sharp & Dohme to buy 300,000 courses of the antiviral drug molnupiravir, pending regulator clearance,
The Australian government signs an agreement with Merck Sharp & Dohme to buy 300,000 courses of the antiviral drug molnupiravir, pending regulator clearance, which would be the first pill to treat COVID-19 patients.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan for full access to every Belfast Herald story and the complete archive.
HealthAustralian government signs an agreement with Merck Sharp & Dohme to buy 300,000 courses of the antiviral drug molnupiravir, pending regulator clearance,
Sign in or subscribeBrowse free archive reportsThe Australian government signs an agreement with Merck Sharp & Dohme to buy 300,000 courses of the antiviral drug molnupiravir, pending regulator clearance, which would be the first pill to treat COVID-19 patients.